Randy Clower


About Randy Clower


Randy V. Clower, PhD, JD, joined the Roswell Park Technology Transfer and Commercial Development Team in 2019, bringing with him over a decade of legal and business-related experience pertaining to the commercialization of proprietary innovations for universities, cancer-centers, and various business entities.

Insofar as many translational technologies require nuanced value-capture strategies—from concept-stage throughout product development and maturation—Dr. Clower’s professional experience concerning federal and state funding initiatives, government policy, administrative guidelines, and experience with foreign and domestic IP statutes, provides a strong framework for assisting inventors and IP owners to achieve their commercial goals. Dr. Clower’s expertise, moreover, involves all forms of IP and commercial negotiations, e.g., licensing and joint-development agreements, as well as assessing market landscapes concerning immuno-oncological innovations, among other biomedical platforms.


Roswell Park Comprehensive Cancer Center
  • Associate General Counsel - Technology Transfer
  • Office of Technology Transfer and Commercial Development


Education and Training:

  • PhD - Microbiology and Immunology, State University of New York at Buffalo, Buffalo, NY
  • JD - Concentrations in Intellectual Property and Technology, State University of New York at Buffalo, Buffalo, NY
  • BS - Molecular Genetics, State University of New York at Fredonia, Fredonia, NY

Board Certification:

  • 2010-present - New York State Bar
  • 2009-present - Wisconsin State Bar
  • 2009-present - United States Patent and Trademark Office (Registered Patent Attorney)

Professional Memberships:

  • 2010-present - American Bar Association Intellectual Property Law Section
  • 2010-present - American Intellectual Property Law Association
  • 2010-present - New York State Bar Association
  • Advisory Board Member - Guideline Medical

Professional Experience:

  • 2018-2019 - President & Founding Member, Clower, PLLC, Buffalo, NY
  • 2017 - 2018 - Intellectual Property Counsel, Integer Holdings Corp. (formerly Greatbatch Medical)
  • 2012-2017 - Special Counsel, Phillips Lytle LLP, Buffalo, NY

Honors & Awards:

  • 2016 - Excellence in Law Award Winner, Up & Coming Attorney, The NY Daily Record
  • 2012 - Recognition for Exceptional Pro Bono Hours, Foley & Lardner, LLP, Madison, WI


Papillomavirus E1 Protein Binds to and Stimulates Human Topoisomerase I, Journal of Virology, Feb 1, 2006;



Cellular Topoisomerase I Modulates Origin Binding by Bovine Papillomavirus Type 1 E1, Journal of Virology · May 1, 2006;



The Papillomavirus E2 Protein Interacts with and Stimulates Human Topoisomerase I, Virology, Apr 1, 2006; https://pubmed.ncbi.nlm.nih.gov/16537084/


Getting Personal With The Future Of Medicine, Metropolitan Corporate Counsel, Aug 12, 2014 http://www.metrocorpcounsel.com/articles/29570/getting-personal-future-medicine/


Top 5 Post AIA Implementation University Considerations, IPWatchdog, Jun 21, 2013



A Landmark Case Comes Down, Metropolitan Corporate Counsel, Jun 20, 2013 http://www.metrocorpcounsel.com/articles/24396/landmark-case-comes-down/


Impending Myriad Decision Portends Promethean Consequences For Biotech Industry, The Metropolitan Corporate Counsel, Feb 22, 2013